{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-078511","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2026-06-29T12:11:25+00:00","discovered_at":"2026-06-29T12:15:00.287057+00:00","generated_at":"2026-06-29T12:15:25.403918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Replimune reports Q4 loss of $73.7M; FDA accepts RP1 BLA resubmission for advanced melanoma","bullets":["Net loss $73.7M in Q4 FY2026; full-year net loss $313.9M.","FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA Aug 2, 2026, advisory cttee in late July.","Cash $268.9M at March 31, 2026; expected runway into Q1 calendar 2027.","IGNYTE-3 (Phase 3) and REVEAL (Phase 2/3) trials enrolling; REVEAL Phase 2/3 transition expected Q1 2027.","ASCO 2026: RP1+nivo 3-yr OS 47.8%, median OS 32.9 mos; RP2 19% ORR in solid tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-078511","json":"https://secwatch.observer/filing/0001104659-26-078511.json","markdown":"https://secwatch.observer/filing/0001104659-26-078511.md","text":"https://secwatch.observer/filing/0001104659-26-078511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/0001104659-26-078511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T12:15:25.403918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}